Fengting Yan. MD, PhD, FACP.
39 posts
Fengting Yan. MD, PhD, FACP.
@FengtingYan
I am interested in personalized care and translational research in women’s cancer. lab & clinical research knowledge apply in my “bench-to-bedside" approach.
Seattle, WA Katılım Temmuz 2021
111 Takip Edilen51 Takipçiler
Fengting Yan. MD, PhD, FACP. retweetledi
In this video, Fengting Yan, MD, PhD, (@FengtingYan) discusses how her clinical practice is informed by data and guidelines available on testing in breast cancer. #bcsm
hubs.li/Q03htJbS0
English
I will be speaking at the Best of Hematology and Breast Cancer 2025 on January 3-4, 2025 in Seattle. My talk will be on 'No' for the Hrt Debate
You can register here: education.binayfoundation.org/Seattle-Hemato…
2
English
A new moonshot to fight cervical cancer is missing something: only one of the sponsors is within reach of the WHO’s recommendation for protecting women. We can and must to better LINK HERE:
statnews.com/2024/11/29/hpv…
@btfoundation @binayshah @ProvSwedish @swedish @sid
English
Fengting Yan. MD, PhD, FACP. retweetledi
Our opinion piece in @statnews highlighting the need for stronger implementation and broader access to HPV vaccination programs to end cervical cancer in the US and across the globe. Thank you @binayshah and @FengtingYan for co-authoring this.
STAT@statnews
The Quad Cancer Moonshot Initiative to fight cervical cancer in the Indo-Pacific region is admirable, but three of the four partners aren’t practicing what they preach. trib.al/FBH0bKs
English
Thank you @YaleCancer for this honor
Yale Cancer Center@YaleCancer
The Yale Cancer Center Award for Mentorship Excellence was presented to @maryam_lustberg, described by @DrEricWiner as “a really remarkable person committed to those she works with” at all levels. bit.ly/43Q4PkS #bcsm @SmilowCancer @YaleMed @YNHH @YaleBreast
English
Poll, how do you pronounce foci? foe-sye or foe-kye?
English
Fengting Yan. MD, PhD, FACP. retweetledi
SENOMAC: SNB +/- ALND in pts with up to 2 macromets
n=2450
Median f/u 47 mo
Median tumor size 20mm (6% T3)
85% had 1 macromet
34.3% with ENE
34.5% had additional LNs on ALND (if 1 SLN 31.3%, if 2 SLN 51.3%)
No difference in 5 yr RFS 88.7% vs 89.7%
#SABCS23 @OncoAlert
English
Glad to see Asian data!
Lilly Oncology Medical@LillyOncMed
At #SABCS23, check out our poster presentation exploring the safety profiles of Chinese breast cancer patients who received a CDK 4 & 6 inhibitor in the MONARCH plus and monarchE trials. See the data here: e.lilly/3RcGCQ9 #bcsm #BreastCancer #CancerResearch
English
Fengting Yan. MD, PhD, FACP. retweetledi
IMP030: Adj chemo+/- atezo in stage 2/3 TNBC
Median f/u 25 mo
iDFS: HR 1.12, p=0.37
iDFS in PDL1+ HR 1.03
Why is there no benefit in the adjuvant setting? Is it PDL1 vs PD1 (unlikely given benefit in IMP031 preop)? Is it that there is no tumor in place?
@OncoAlert #SABCS23
English
Fengting Yan. MD, PhD, FACP. retweetledi
HER2CLIMB-02: The addition of tucatinib to T-DM1 significantly improved PFS (9.5 vs 7.4 months, HR 0.76, p=0.016) in patients with HER2+ MBC. OS curves look reverted (HR 1.23), though immature. Significant increase in the rate of severe liver toxicities and diarrhea. Poll below👇
English
Fengting Yan. MD, PhD, FACP. retweetledi
monarchE: ctDNA at baseline + 24 mo in a subset of pts
Detection of ctDNA at baseline soon after completion of neo/adjuvant tx: 10/178 (5.6%)
3 of 10 cleared ctDNA + none recurred
7 of 10 had persistence + all recurred
#SABCS23 @OncoAlert #bcsm
English
Fengting Yan. MD, PhD, FACP. retweetledi
MONARCH3: AI +/- abemaciclib
Final OS analysis
Median follow-up 8.1 years
66.8 vs 53.7 mo
Absolute Difference 13.1 mo
Not statistically significant
23.3% progression free at 6 yrs on the abemaciclib arm
@oncolaert #SABCS23
English
Recommending a book, so well written - I am honored to claim that I know the author (to be accurate, the author’s family).
English
Fengting Yan. MD, PhD, FACP. retweetledi
Fengting Yan. MD, PhD, FACP. retweetledi
Outstanding discussion on Checkmate7FL & KEYNOTE-756 by Stephen Johnston. Impressive pCR results, but need to wait for survival endpoints to understand the ultimate benefit. And when we talk about PD-L1 exp, it’s key to understand the assay & thresholds.
English
Fengting Yan. MD, PhD, FACP. retweetledi
SKB264 (MK-2870) TROP 2 ADC with belatecan topoI payload DAR 7.4: phase 2 of 5 mg/kg q2wk in mBC HR+
n=38
ORR 36.8%
mPFS 11.1 mo
36% g3/4 neutropenia
#ESMO23 @OncoAlert #bcsm
English
Fengting Yan. MD, PhD, FACP. retweetledi
Beautiful presentation by @nlinmd on OP-1250 (palezestrant) in HR+ mBC
RP2D
42% >= 3L prior tx
CBR 40%
PFS 4.6 mo (5.6mo ESR1m)
@OncoAlert @DFCI_BreastOnc #ESMO23
English
Fengting Yan. MD, PhD, FACP. retweetledi
VIDEO: ‘Beyond proud’: Family, friends unveil memorial to remember couple killed in Gorge shooting kiro7.com/news/local/vid…
English